Gabapentin and breastfeeding: a case report.
The aim of this study was to describe the milk-plasma ratio and relative infant dose of gabapentin in a breastfeeding mother and to determine the well-being of her exposed infant. The mother-infant pair was studied over a 24-hour dose interval at steady state. Gabapentin concentrations were quantified by high-performance liquid chromatography. Infant exposure was calculated as concentration in milk multiplied by an estimated milk production of 0.15 L/kg/d and normalized to the weight-adjusted maternal dose. The milk-plasma ratio was 0.86; the relative infant dose was 2.34%. The absolute infant dose was approximately 3% of the children's dose for gabapentin, and the infant plasma level of 0.4 mg/L was approximately 6% of the maternal plasma drug concentration. No adverse effects attributable to gabapentin were noted in the infant. In combination with a previously published report, these limited data support the prescription of gabapentin to a breastfeeding mother after a careful individual risk-benefit analysis.
Kristensen
Judith H
JH
Department of Pharmacy at the Women's and Children's Health Service, Subiaco, Western Australia.
Ilett
Kenneth F
KF
Hackett
L Peter
LP
Kohan
Rolland
R
D000328:Adult; D000588:Amines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000700:Analgesics / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001416:Back Pain / Q000188:drug therapy; D001942:Breast Feeding; D003509:Cyclohexanecarboxylic Acids / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007223:Infant; D007774:Lactation / Q000378:metabolism*; D008297:Male; D008895:Milk, Human / Q000737:chemistry* / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin